tiprankstipranks
Advertisement
Advertisement
Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target
PremiumRatingsRevolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target
20d ago
Revolution Medicines price target raised to $210 from $179 at Truist
Premium
The Fly
Revolution Medicines price target raised to $210 from $179 at Truist
22d ago
Revolution Medicines price target raised to $235 from $183 at Needham
Premium
The Fly
Revolution Medicines price target raised to $235 from $183 at Needham
23d ago
Revolution Medicines price target raised to $195 from $165 at Oppenheimer
PremiumThe FlyRevolution Medicines price target raised to $195 from $165 at Oppenheimer
2M ago
Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target
Premium
Ratings
Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target
2M ago
Charles Zhu Reiterates Buy on RVMD, Maintains $263 Price Target on Strong Darax Data and Regulatory Progress
Premium
Ratings
Charles Zhu Reiterates Buy on RVMD, Maintains $263 Price Target on Strong Darax Data and Regulatory Progress
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100